Business Wire

St. Jude Medical Announces Data to be Presented as Late-Breaking Clinical Trials and Highlights Its Latest Cardiovascular Portfolio at the 2016 TCT Conference

24.10.2016 12:00 | Business Wire

Del

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that it will have new data featured during late-breaking clinical trial presentations at the upcoming 2016 Transcatheter Cardiovascular Therapeutics educational meeting in Washington, D.C., October 29 – November 2. Throughout the congress, the company will also feature its latest cardiovascular innovations, including PressureWire™ X guidewire, the latest generation of the pioneering PressureWire guidewire system; structural heart solutions and the CardioMEMS™ HF System.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161024005224/en/

St. Jude Medical will have new data featured during late-breaking clinical trial presentations at th ...

St. Jude Medical will have new data featured during late-breaking clinical trial presentations at the upcoming 2016 Transcatheter Cardiovascular Therapeutics symposium. Throughout the congress, the company will also feature its latest cardiovascular innovations that demonstrate its commitment to transforming the treatment of cardiovascular disease. (Photo: Business Wire)

Three late-breaking or first report investigation sessions and one oral abstract presentation will highlight data from St. Jude Medical advancements in vascular and structural heart technologies.

  • A comparison of stent visualization technologies for use during percutaneous coronary intervention (PCI) – Data from the first randomized clinical trial to compare OCT-guided, IVUS-guided and angiography-guided PCI

The session: “ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation in Patients with Coronary Artery Disease,” will be presented by Dr. Ziad A. Ali, associate director of translational medicine at the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York at 9 a.m. on Sunday, October 30. This is the first late-breaking clinical trial presentation of TCT 2016.

  • Final long term results from the RESPECT trial, comparing recurrent stroke in patients with the AMPLATZER™ PFO closure device to contemporary medical management

The session: “RESPECT: Final Long-Term Outcomes from a Prospective, Randomized Trial of PFO Closure in Patients with Cryptogenic Stroke,” will be presented by Dr. David Thaler, neurologist-in-chief at Tufts Medical Center and chairman of the Department of Neurology at Tufts University School of Medicine in Boston, at 12:15 p.m. on Tuesday, November 1.

Previous results observed a stroke reduction across the totality of analyses with rates ranging from 51-73 percent.

  • Initial data from the largest, prospective evaluation of the AMPLATZER™ Amulet™ LAA occluder device, designed to seal the left atrial appendage to prevent stroke in patients with non-valvular atrial fibrillation

The session: “AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation,” will be presented by Dr. David Hildick-Smith, cardiologist at Brighton & Sussex University Hospitals in the UK, at 9:40 a.m. on Wednesday, November 2.

Leading interventional cardiologists will also be on hand to demonstrate the OPTIS™ integrated system from 10-11 a.m. and from 2-3 p.m. each day during exhibit hours (Sunday, Oct. 30, Monday, October 31 and Tuesday, November 1).

Additionally, on Sunday, October 31, St. Jude Medical is sponsoring a TCT satellite symposium, "Interventional management of complex patients, cutting edge technologies for the advanced interventionalist.” For more information about this event, visit: http://www.crf.org/tct/agenda/satellite-programs.

About St. Jude Medical

St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management, and cardiovascular. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the company, including potential clinical successes, reimbursement strategies, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the company’s control and the risk factors and other cautionary statements described in the company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 2, 2016. The company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Contact information

St. Jude Medical, Inc.
J.C. Weigelt, 651-756-4347
Investor Relations
jweigelt@sjm.com
or
Gina O’Connell, 651-756-3380
Media Relations
Goconnell02@sjm.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04Pressemelding

Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We

Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57Pressemelding

Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio

Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08Pressemelding

On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c

PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence17.8.2017 07:00Pressemelding

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US. Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia

Smarsh Adds Voice Archiving Offering with Acquisition of London-Based Cognia17.8.2017 06:59Pressemelding

Smarsh®, providing information archiving solutions for compliance, e-discovery and risk management, has completed the acquisition of Cognia, a worldwide leader in cloud-based voice archiving, audio search and analytics. Smarsh will leverage Cognia’s intellectual property and development resources to offer its global customer base enhanced capabilities around mobile and fixed-line voice communication – alongside a market-leading range of electronic communications – within The Archiving Platform. The acquisition will expand the existing presence of Smarsh in Europe and is central to its MiFID II compliance solution for financial firms. In addition to capturing incoming and outgoing communication from fixed-line recording solutions, Cognia uniquely captures voice content directly from leading mobile carriers. Carrier-direct capture is the most reliable and automated method for capt

Schlumberger Announces Third-Quarter 2017 Results Conference Call16.8.2017 21:23Pressemelding

Schlumberger Limited (NYSE:SLB) will hold a conference call on October 20, 2017 to discuss the results for the third quarter ending September 30, 2017. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call,

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom